Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents

References

• Vos CG, Vahl A. Anticoagulation and antiplatelet therapy in patients with peripheral arterial disease of the femoro-popliteal arteries. J Cardiovasc Surg (Torino) 2017. [Epub ahead of print]. doi: 10.23736/S0021-9509.17.10210-7
   Web of Science ®Google Scholar
• Bezin J, Klungel OH, Lassalle R, et al. Medications recommended for secondary prevention after first acute coronary syndrome: effectiveness of treatment combinations in a real-life setting. Clin Pharmacol Ther 2017. [Epub ahead of print]. doi: 10.1002/cpt.864
   PubMed Web of Science ®Google Scholar
• Shrestha S, Coy S, Bekelis K. Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke. Curr Pharm Des 2017;23:1377–91.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531–40.
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27–33.
   PubMed Web of Science ®Google Scholar
• Nordeen JD, Patel AV, Darracott RM, et al. Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol 2013;6:26–34.
   PubMedGoogle Scholar
• Béres BJ, Tóth-Zsámboki E, Vargová K, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost 2008;100:829–38.
   PubMed Web of Science ®Google Scholar
• Marketou ME, Kintsurashvili E, Androulakis NE, et al. Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism. Int J Cardiol 2013;168:2561–6.
   PubMed Web of Science ®Google Scholar
• Marketou M, Kochiadakis G, Kintsurasvili E, et al. Blockade of platelet alpha2B-adrenergic receptors in patients with coronary artery disease: a novel antiaggregant mechanism. Eur Heart J 2013;34(suppl 1):574. doi: 10.1093/eurheartj/eht309.P3138
   Google Scholar
• Goto S, Ikeda Y, Murata M, et al. Epinephrine augments von Willebrand factor-dependent shear-induced platelet aggregation. Circulation 1992;86:1859–63.
   PubMed Web of Science ®Google Scholar
• Mustonen P, Lassila R. Epinephrine augments platelet recruitment to immobilized collagen in flowing blood–evidence for a von Willebrand factor-mediated mechanism. Thromb Haemost 1996;75:175–81.
   PubMed Web of Science ®Google Scholar
• Menziani MC, Montorsi M, De Benedetti PG, Karelson M. Relevance of theoretical molecular descriptors in quantitative structure-activity relationship analysis of alpha1-adrenergic receptor antagonists. Bioorg Med Chem 1999;7:2437–51.
   PubMed Web of Science ®Google Scholar
• Wang CD, Buck MA, Fraser CM. Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 1991;40:168–79.
   PubMed Web of Science ®Google Scholar
• Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009;459:356–63.
   PubMed Web of Science ®Google Scholar
• Bylund DB, Ray-Prenger C, Murphy TJ. Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 1988;245:600–7.
   PubMed Web of Science ®Google Scholar
• Li M-Y, Tsai K-C, Xia L. Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett 2005;15:657–64.
   PubMed Web of Science ®Google Scholar
• Carruthers SG. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf 1994;11:12–20.
   PubMed Web of Science ®Google Scholar
• Waszkielewicz AM, Kubacka M, Pańczyk K, et al. Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems. Bioorg Med Chem Lett 2016;26:5315–21.
   PubMed Web of Science ®Google Scholar
• Bednarski M, Otto M, Dudek M, et al. Synthesis and pharmacological activity of a new series of 1-(1H-Indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol analogs. Arch Pharm (Weinheim) 2016;349:211–23.
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Ayala D, Benhamu B, et al. Arylpiperazine derivatives acting at 5-HT(1A) receptors 5. Curr Med Chem 2002;9:443–69.
   PubMed Web of Science ®Google Scholar
• Huff JR, Baldwin JJ, deSolms SJ, et al. Structure-affinity relationships of arylquinolizines at alpha-adrenoceptors. J Med Chem 1988;31:641–5.
   PubMed Web of Science ®Google Scholar
• Cockroft SL, Perkins J, Zonta C, et al. Substituent effects on aromatic stacking interactions. Org Biomol Chem 2007;5:1062–80.
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 5.(1) Study of the physicochemical influence of the pharmacophore on 5-HT(1A)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1A)/D(2) antagonist properties. J Med Chem 2001;44:186–97.
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors. J Med Chem 2005;48:2548–58.
   PubMed Web of Science ®Google Scholar
• Ostopovici-Halip L, Curpăn R, Mracec M, Bologa CG. Structural determinants of the alpha2 adrenoceptor subtype selectivity. J Mol Graph Model 2011;29:1030–8.
   PubMed Web of Science ®Google Scholar
• Xhaard H, Nyrönen T, Rantanen V-V, et al. Model structures of α-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. J Struct Biol 2005;150:126–43.
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Bucki A, Feder M, Pawłowski M. Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening. J Chem Inf Model 2013;53:638–48.
   PubMed Web of Science ®Google Scholar
• Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318:1258–65.
   PubMed Web of Science ®Google Scholar
• Kurowski MA, Bujnicki JM. GeneSilico protein structure prediction meta-server. Nucleic Acids Res 2003;31:3305–7.
   PubMed Web of Science ®Google Scholar
• Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinforma Oxf Engl 2006;22:195–201.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 2003;92:967–74.
   PubMed Web of Science ®Google Scholar
• Borchardt RT, Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology, 96, 736-749, 1989–the backstory. AAPS J 2011;13:323–7.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46–58.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng H-Y, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Shahpouri MM, Mousavi S, Khorvash F, et al. Anticoagulant therapy for ischemic stroke: a review of literature. J Res Med Sci off J Isfahan Univ Med Sci 2012;17:396–401.
   Google Scholar